Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/217705
COMPARTIR / EXPORTAR:
logo share SHARE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Multiple Myeloma and SARS-CoV-2 Infection: Clinical Characteristics and Prognostic Factors of Inpatient Mortality

Otros títulosMM, SARS-CoV-2 infection, and inpatient mortality
AutorMartínez-López, Joaquín; Mateos, Maria Victoria; Encinas, Cristina; Sureda, Anna; Hernández-Rivas, José Ángel; López de la Guía, Ana; Conde, Diego; Krsnik, Isabel; Prieto, Elena; Riaza Grau, Rosalía; Gironella, Mercedes; Blanchard, María Jesús; Caminos, Nerea; Fernández de Larrea, Carlos; Senin, María Alicia; Escalante, Fernando; Puerta, José Enrique de la; Gimenez, Eugenio; Martínez-Barranco, Pilar; Mateos, Juan José; Casado, Luis Felipe; Bladé, Joan; Lahuerta, Juan José; Cruz, Javier de la; San-Miguel, Jesús
Fecha de publicación30-jun-2020
EditorMedRxiv
ResumenThere is limited information on the characteristics, pre-admission prognostic factors, and outcomes of patients with multiple myeloma (MM) hospitalized with coronavirus disease 2019 (COVID-19). This retrospective case series investigated characteristics and outcomes of 167 MM patients hospitalized with COVID-19 reported from 73 hospitals within the Spanish Myeloma Collaborative Group network in Spain between March 1 and April 30, 2020. Outcomes were compared with a randomly selected contemporary cohort of 167 age-/sex-matched non-cancer patients with COVID-19 admitted at 6 participating hospitals. Common demographic, clinical, laboratory, treatment, and outcome variables were collected; specific disease status and treatment data were collected for MM patients. Among the MM and non-cancer patients, median age was 71 years and 57% of patients were male in each series, and 75% and 77% of patients, respectively, had at least one comorbidity. COVID-19 clinical severity was moderate-severe in 77% and 89% of patients and critical in 8% and 4%, respectively. Supplemental oxygen was required by 47% and 55% of MM and non-cancer patients, respectively, and 21%/9% vs 8%/6% required non-invasive/invasive ventilation. Inpatient mortality was 34% and 23% in MM and non-cancer patients, respectively. Among MM patients, inpatient mortality was 41% in males, 42% in patients aged >65 years, 49% in patients with active/progressive MM at hospitalization, and 59% in patients with comorbid renal disease at hospitalization, which were independent prognostic factors of inpatient mortality on adjusted multivariate analysis. This case series demonstrates the increased risk and identifies predictors of inpatient mortality among MM patients hospitalized with COVID-19.
Versión del editorhttps://doi.org/10.1101/2020.06.29.20142455
URIhttp://hdl.handle.net/10261/217705
DOI10.1101/2020.06.29.20142455
Aparece en las colecciones: (IBMCC) Artículos
(PTI Salud Global) Colección Especial COVID-19




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Multiple Myeloma_MartinezLopez.pdf544,05 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

Page view(s)

130
checked on 28-mar-2024

Download(s)

126
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Este item está licenciado bajo una Licencia Creative Commons Creative Commons